On May 21, 2020, BioAegis Therapeutics announced that the National Institute of Health Clinical Center began measuring patient gelsolin levels as part of the NIAID Strategic Plan for COVID-19 Research. BioAegis’ lead product, recombinant human plasma gelsolin (rhu-pGSN), is based on this highly abundant circulating human protein.

This study was a critical step in a large international collaborative to understand the immune response during COVID-19 infection and convalescence.